Federal contract award
75A50118C00024
IGF::OT::IGF
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $56.7M |
| Current contract value | $56.7M |
| Potential contract value / ceiling | $62.5M |
| Start date | Sep 25, 2018 |
| Current end date | Dec 31, 2024 |
| Potential end date | Dec 31, 2024 |
| Latest award activity | May 7, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| May 7, 2026 | P00026 | $0 | UPDATE INDIRECT RATES AND FAR & HHSAR CLAUSES ON CONTRACT |
| Apr 10, 2025 | P00025 | $0 | MAPP BIOPHARMACEUTICAL, INC. - TRANSFER GFP FROM CONTRACT HHSO100201800024C TO CONTRACT 75A50122C00061 AND UPDATE CLAUSES ON CONTRACT ADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTER |
| Oct 23, 2024 | P00024 | $0 | ADVANCE MBP134, A COCKTAIL OF TWO HUMAN MONOCLONAL ANTIBODIES (MBP047 AND MBP087), AS A POTENTIAL MEDICAL COUNTERMEASURE TO TREAT ACTIVE INFECTIONS OF SUDAN VIRUS - UPDATE INDIRECT RATES LETTER |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.